Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Mais filtros

Intervalo de ano de publicação
Am J Case Rep ; 19: 634-637, 2018 Jun 02.
Artigo em Inglês | MEDLINE | ID: mdl-29858491


BACKGROUND Pseudoepitheliomatous hyperplasia (PEH) is a reactive epithelial proliferation occurring secondary to infection, neoplasm, injury, and inflammation. The histopathological characteristics of PEH may lead to it being confused with well-differentiated squamous cell carcinoma (SCC). CASE REPORT We present here the case of a 57-year-old male patient, who was diabetic and a smoker, who presented with dysphonia. Although nasal endoscopy suggested SCC, morphological and immunophenotypical study of biopsy tissue ruled out malignancy. CONCLUSIONS As the prognosis worsened, the patient required several urgent surgical interventions due to bleeding abscesses and dyspnea. A total laryngectomy was performed.

Hiperplasia/cirurgia , Doenças da Laringe/cirurgia , Laringectomia , Laringe/cirurgia , Proliferação de Células , Células Epiteliais/patologia , Humanos , Hiperplasia/etiologia , Hiperplasia/patologia , Doenças da Laringe/patologia , Laringe/patologia , Masculino , Pessoa de Meia-Idade
J Reprod Immunol ; 125: 100-105, 2018 02.
Artigo em Inglês | MEDLINE | ID: mdl-29241813


Allergic asthma is an increasing health problem worldwide. Interestingly, prenatal challenges such as stress have been associated with an increased risk for asthma during childhood. The underlying pathogenesis of how prenatal stress increases the risk for asthma still remains unclear. Potential targets could be that the fetal immune ontogeny or fetal lung development are compromised by prenatal challenges. Here, we aimed to identify whether prenatal stress challenge affects fetal lung development in mice. C57BL/6 pregnant mice were challenged with sound stress and fetal lung development was assessed histologically. Whilst prenatal stress challenge did not profoundly affect lung development in male fetuses, it resulted in less extensive terminal sacs, surrounded by thicker mesenchymal tissue in female fetuses. Thus, prenatal stress disrupted fetal lung development sex-specifically. Interestingly, upon prenatal stress challenge, the airway hyperresponsiveness and eosinophilic inflammation- two hallmarks of asthma - were significantly increased in adult female offspring, whilst regulatory CD4+ T cells were reduced. These findings strongly underpin the sex-specific association between s challenged fetal development and a sex-specific altered severity of asthma in adult offspring. Our model now allows to identify maternal markers through which the risk for asthma and possible other diseases is vertically transferred before birth in response to challenges. Such identification then opens avenues for primary disease prevention.

Asma/diagnóstico , Desenvolvimento Fetal/imunologia , Pulmão/embriologia , Efeitos Tardios da Exposição Pré-Natal/diagnóstico , Estresse Psicológico/imunologia , Estimulação Acústica/efeitos adversos , Animais , Asma/sangue , Asma/imunologia , Asma/patologia , Linfócitos T CD4-Positivos/imunologia , Modelos Animais de Doenças , Feminino , Humanos , Pulmão/imunologia , Pulmão/patologia , Masculino , Exposição Materna/efeitos adversos , Camundongos , Camundongos Endogâmicos C57BL , Gravidez , Efeitos Tardios da Exposição Pré-Natal/sangue , Efeitos Tardios da Exposição Pré-Natal/imunologia , Efeitos Tardios da Exposição Pré-Natal/patologia , Índice de Gravidade de Doença , Globulina de Ligação a Hormônio Sexual
Genes (Basel) ; 8(10)2017 Sep 28.
Artigo em Inglês | MEDLINE | ID: mdl-28956815


The Transcription factor BarH like homeobox 1 (BARHL1) is overexpressed in medulloblastoma and plays a role in neurogenesis. However, much about the BARHL1 regulatory networks and their functions in neurodegenerative and neoplastic disorders is not yet known. In this study, using a tissue microarray (TMA), we report for the first time that BARHL1 is downregulated in hormone-negative breast cancers and Alzheimer's disease (AD). Furthermore, using an integrative bioinformatics approach and mining knockout mouse data, we show that: (i) BARHL1 and Estrogen Receptor 1 (ESR1) may constitute a network that regulates Neurotrophin 3 (NTF3)- and Brain Derived Neurotrophic Factor (BDNF)-mediated neurogenesis and neural survival; (ii) this is probably linked to AD pathways affecting aberrant post-translational modifications including SUMOylation and ubiquitination; (iii) the BARHL1-ESR1 network possibly regulates ß-amyloid metabolism and memory; and (iv) hsa-mir-18a, having common key targets in the BARHL1-ESR1 network and AD pathway, may modulate neuron death, reduce ß-amyloid processing and might also be involved in hearing and cognitive decline associated with AD. We have also hypothesized why estrogen replacement therapy improves AD condition. In addition, we have provided a feasible new mechanism to explain the abnormal function of mossy fibers and cerebellar granule cells related to memory and cognitive decline in AD apart from the Tau and amyloid pathogenesis through our BARHL1-ESR1 axis.

J Immunother ; 26(2): 139-48, 2003.
Artigo em Inglês | MEDLINE | ID: mdl-12616105


Epidermal growth factor receptor (EGFR) overexpression has been detected in many tumors of epithelial origin, and it is often associated with tumor growth advantages and poor prognosis. h-R3 is a genetically engineered humanized antibody (mAb) that recognizes an epitope located in the extracellular domain of human EGFR. The antibody exhibited potent in vitro and in vivo antitumor effect on EGFR overexpressing cell lines. To study safety, pharmacokinetics, and biodistribution, 12 patients with advanced epithelial-derived tumors received single intravenous infusion of h-R3 at four dose levels. Safety evaluation was made according to World Health Organization toxicity criteria. For biodistribution, 3 mg of the total dose were labeled with Technetium and then pooled with the rest of the dose. Anterior and posterior whole-body images were acquired using a gamma camera. Blood samples were taken for pharmacokinetics, antiidiotypic response, and for soluble EGFR detection. After hR3 administration, no evidence of severe toxicity was observed. Secondary reactions were mild and moderate and mainly consisted of tremors, fever, and vomiting. No anaphylactic or skin reactions were detected. Qualitative analysis of whole-body images showed that the liver had the highest mAb uptake. Pharmacokinetic analysis revealed that elimination half-lives and the AUC increased linearly with dose, while total body clearance decreased when increasing doses of h-R3. No relation between shed EGFR and mAb clearance was found. No antiidiotypic response against h-R3 was detected. Several phase II trials are now underway to evaluate the efficacy of h-R3 in the treatment of advanced cancer patients.

Anticorpos Monoclonais/administração & dosagem , Anticorpos Monoclonais/farmacocinética , Carcinoma/terapia , Receptores ErbB/administração & dosagem , Neoplasias/terapia , Adulto , Idoso , Disponibilidade Biológica , Carcinoma/imunologia , Carcinoma/patologia , Relação Dose-Resposta a Droga , Esquema de Medicação , Receptores ErbB/sangue , Feminino , Seguimentos , Humanos , Infusões Intravenosas , Masculino , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Neoplasias/imunologia , Neoplasias/patologia , Medição de Risco , Resultado do Tratamento
Acta méd. colomb ; 18(5): 244-9, sept.-oct. 1993. tab
Artigo em Espanhol | LILACS | ID: lil-183309


OBJETIVO: demostrar la eficacia y seguridad del fluconazol en la profilaxis de la candidiasis orofaríngea en pacientes con neoplasia hematológica e inmunosuprimidos médicamente. DISEÑO: estudio doble ciego, prospectivo, comparativo con placebo. UBICACION: consulta externa de las instituciones que que participaron. PACIENTES: 53 pacientes ambulatorios con neoplasia hematológica, sin candidiasis orofarígea, comprobada por microbiología, a los cuales se les iniciaba ciclo terapéutico con antineoplásicos. INTERVENCION: doble ciego al azar; administración de 10 ml de jarabe en dosis única diaria conteniendo 50 mg de fluconazol o excipientes, durante todo el período de tratamiento antimicótico tópico o sistémico asociado. PRINCIPAL RESULTADO A EVALUAR: evitar la candidiasis orofarígea. RESULTADOS: 53 pacientes estudiados; 26 recibieron fluconazol y 27 placebo, CLINICA:ninguno de los pacientes que recibieron fluconazol presentó cuadro clínico durante tratamiento; cuatro de los que recibieron placebo sí la presentaron (p<0.02 en favor de fluconazol); adicionalmente, una paciente presentó candiduria y cuadro séptico, obligando a abrir el código. Fue tratada con fluconazol parenteral y curó en corto tiempo. MICROBIOLOGIA: frotis pretratamiento: un paciente colonizado en el grupo placebo (X²=no significativo); postratamiento, cuatro pacientes del grupo placebo tenían presencia de levaduras (P<0.05,en favor de fluconazol). Solo uno de los cultivos pretratamiento se apreció crecimiento, uno de ellos masivo (p<0.05,en favor de fluconazol). SEGURIDAD : cuatro pacientes presentaron eventos adversos. Tres fueron en el grupo que recibió fluconazol, uno de los cuales presentó vómito severo que obligo a la suspensión del tratamiento; otro, disnea moderada asociada a obstrucción de vías aéreas por reacción anafiláctica relacionada con administración concomitante de penicilina, y otro ictericia leve, que cedió espontáneamente al suspender el tratamiento. El otro paciente, que estaba recibiendo placebo, presentó dolores abdominales, tipo cólico, posiblemente relacionados con el empleo concomitante de un antiparasitario. CONCLUSIONES : el fluconazol en dosis única diaria de 50 mg durante el período de terapía inmunosupresora, demostró ser eficaz como profiláctico de la candidiasis orofaríngea, además de fácil cumplimiento por el paciente y muy bien tolerado.

Humanos , Candidíase Bucal/classificação , Candidíase Bucal/complicações , Candidíase Bucal/diagnóstico , Candidíase Bucal/tratamento farmacológico , Candidíase Bucal/epidemiologia , Candidíase Bucal/etiologia , Candidíase Bucal/microbiologia , Candidíase Bucal/fisiopatologia , Candidíase Bucal/terapia , Fluconazol/administração & dosagem , Fluconazol/efeitos adversos , Fluconazol , Fluconazol/farmacocinética , Fluconazol/farmacologia , Fluconazol/uso terapêutico
Rev. cuba. med ; 20(2): 190-6, mar.-abr. 1981. ilus, tab
Artigo em Espanhol | CUMED | ID: cum-11894


Se exponen los resultados obtenidos en 90 pacientes a quienes se les realizó GG pulmonar con 67 Ga-citrato. El material se presenta en forma de cuadrados e ilustraciones. La positividad global fue de 52,2 porciento; en los casos de tumores primitivos broncopulmonares la positividad inicial fue de 65,9 porciento, ésta llega al 80,5 porciento al no tomarse en cuenta los GG dudosos de interpretación. Se analizan y discuten los resultados. Concluyen expresando la utilidad clínica del 67 Ga-citrato en el estudio de los tumores broncopulmonares, en la evolución del tratamiento realizado y la posibilidad de detectar recidivas tumorales luego de la terapéutica inicial(AU)

Humanos , Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Idoso , Neoplasias Pulmonares , Radioisótopos de Gálio